SCHEMBL15345003

SCHEMBL15345003

Cc1cncc(N2CCN(C(C)C)CC2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.46
ALDH1A1 P00352 1/20 0.46
MAPT P10636 1/20 0.46
PKM P14618 1/20 0.46
TGFBR1 P36897 3/20 0.45
ACVR1 Q04771 3/20 0.45
KCNH2 Q12809 1/20 0.45
CHRNB2 P17787 4/20 0.44
CHRNA4 P43681 4/20 0.44
CHRNB4 P30926 3/20 0.44
CHRNA3 P32297 3/20 0.44
KHK P50053 1/20 0.41
HRH3 Q9Y5N1 3/20 0.38
CYP3A4 P08684 1/20 0.38
BMPR1B O00238 1/20 0.37
BMPR1A P36894 1/20 0.37
ACVR1B P36896 1/20 0.37
ACVRL1 P37023 1/20 0.37
TNIK Q9UKE5 1/20 0.37
TLR9 Q9NR96 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13436493 0.82 CHRNB2 (0.42) CHRNB2CHRNA4CHRNB4CHRNA3HRH3
SCHEMBL13778275 0.82 TGFBR1 (0.54) KDM4EALDH1A1MAPTPKMTGFBR1
SCHEMBL12326041 0.81 KDM4E (0.45) KDM4EALDH1A1MAPTPKMTGFBR1
SCHEMBL13436330 0.81 KDM4E (0.45) KDM4EALDH1A1MAPTPKMTGFBR1
SCHEMBL12321710 0.81 CHRNB2 (0.55) KDM4EALDH1A1MAPTPKMTGFBR1
SCHEMBL6883566 0.80 NOS3 (0.51) KDM4EALDH1A1MAPTTGFBR1ACVR1
SCHEMBL13980884 0.80 CHRNB2 (0.50) CHRNB2CHRNA4CHRNB4CHRNA3
SCHEMBL20153303 0.80 CHRNB2 (0.50) CHRNB2CHRNA4CHRNB4CHRNA3CYP3A4
SCHEMBL13778337 0.78 CHRNB2 (0.49) CHRNB2CHRNA4CHRNB4CHRNA3
SCHEMBL27921191 0.78 KDM4E (0.52) KDM4EALDH1A1MAPTPKMTGFBR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3070081-B1 BENZOTHIAZOL-6-YL ACETIC ACID DERIVATIVES AND THEIR USE FOR TREATING AN HIV INFECTION GILEAD SCIENCES INC (US) 2018-02-28 EP disclosed
US-20160015690-A1 THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. 2016-01-21 US disclosed
US-8987250-B2 Therapeutic compounds GILEAD SCIENCES, INC. (US) 2015-03-24 US disclosed
US-20130281433-A1 THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. 2013-10-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160015690-A1 THERAPEUTIC COMPOUNDS NQO1, HAVCR2, CCR5 KDM4E 4221/4885ALDH1A1 355/4885MAPT 1627/4885
US-20130281433-A1 THERAPEUTIC COMPOUNDS NQO1, HAVCR2, CCR5 KDM4E 4221/4885ALDH1A1 355/4885MAPT 1627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.